Literature DB >> 11282273

Steroid receptors and metastatic potential in endometrial cancers.

J Fujimoto1, H Sakaguchi, I Aoki, S Khatun, H Toyoki, T Tamaya.   

Abstract

The relative overexpression of estrogen receptor (ER)-alpha exon 5 splicing variant, the disrupted synchronization of ER-beta and ER-alpha expressions, and the suppression of progesterone receptor (PR) form A expression as a transcriptional repressor might be related to metastatic potential of uterine endometrial cancers, leading to poor patient prognosis related to estrogen refractoriness.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11282273     DOI： 10.1016/s0960-0760(00)00176-x

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN： 0960-0760            Impact factor:   4.292


  4 in total

1.  Characterization of LHY-821, a novel moderately differentiated endometrial carcinoma cell line.

Authors:  Qian Hu; Li Yu; Rui Chen; Yan Zhang; Ya Xie; Qinping Liao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-07-18       Impact factor: 2.416

2.  Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells.

Authors:  Susan M Dougherty; Williard Mazhawidza; Aimee R Bohn; Krista A Robinson; Kathleen A Mattingly; Kristy A Blankenship; Mary O Huff; William G McGregor; Carolyn M Klinge
Journal:  Endocr Relat Cancer       Date:  2006-03       Impact factor: 5.678

3.  Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.

Authors:  Hila Kreizman-Shefer; Jana Pricop; Shlomit Goldman; Irit Elmalah; Eliezer Shalev
Journal:  Diagn Pathol       Date:  2014-03-31       Impact factor: 2.644

4.  Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro.

Authors:  Marie-Claude Dery; Celine Van Themsche; Diane Provencher; Anne-Marie Mes-Masson; Eric Asselin
Journal:  Reprod Biol Endocrinol       Date:  2007-09-25       Impact factor: 5.211
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.